Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

NCT03205046 is registered in ClinicalTrials.gov with Acerta Pharma BV as lead sponsor.

NCT NCT03205046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03205046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
Lead sponsor
Acerta Pharma BV
Phase
Phase 1/2
Overall status
Terminated
Start date
June 29, 2017
Completion date
November 20, 2019
Enrollment
25 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

dlbcl, richter syndrome